Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS TM Miller, ME Cudkowicz, A Genge, PJ Shaw, G Sobue, RC Bucelli, ... New England Journal of Medicine 387 (12), 1099-1110, 2022 | 298 | 2022 |
Study of 962 patients indicates progressive muscular atrophy is a form of ALS WK Kim, X Liu, J Sandner, M Pasmantier, J Andrews, LP Rowland, ... Neurology 73 (20), 1686-1692, 2009 | 239 | 2009 |
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials LH Van Den Berg, E Sorenson, G Gronseth, EA Macklin, J Andrews, ... Neurology 92 (14), e1610-e1623, 2019 | 136 | 2019 |
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis JA Andrews, CE Jackson, TD Heiman-Patterson, P Bettica, BR Brooks, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21 (7-8), 509-518, 2020 | 111 | 2020 |
Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort J Murphy, P Factor-Litvak, R Goetz, C Lomen-Hoerth, PL Nagy, J Hupf, ... Neurology 86 (9), 813-820, 2016 | 100 | 2016 |
CK‐2127107 amplifies skeletal muscle response to nerve activation in humans JA Andrews, TM Miller, V Vijayakumar, R Stoltz, JK James, L Meng, ... Muscle & Nerve 57 (5), 729-734, 2018 | 80 | 2018 |
Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients R Reich-Slotky, J Andrews, B Cheng, R Buchsbaum, D Levy, P Kaufmann, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 14 (3), 212-216, 2013 | 76 | 2013 |
Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis JA Andrews, L Meng, SF Kulke, SA Rudnicki, AA Wolff, ME Bozik, FI Malik, ... JAMA neurology 75 (1), 58-64, 2018 | 73 | 2018 |
Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study M Benatar, J Wuu, PM Andersen, RC Bucelli, JA Andrews, M Otto, ... Neurotherapeutics 19 (4), 1248-1258, 2022 | 69 | 2022 |
Amyotrophic lateral sclerosis: Update on clinical management SP Norris, MFN Likanje, JA Andrews Current opinion in neurology 33 (5), 641-648, 2020 | 69 | 2020 |
Respiratory measures in amyotrophic lateral sclerosis N Lechtzin, ME Cudkowicz, M de Carvalho, A Genge, O Hardiman, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19 (5-6), 321-330, 2018 | 64 | 2018 |
Experience with the Awaji Island modifications to the ALS diagnostic criteria A Chen, L Weimer, T Brannagan III, M Colin, J Andrews, H Mitsumoto, ... Muscle & nerve 42 (5), 831-832, 2010 | 60 | 2010 |
Amyotrophic lateral sclerosis: clinical management and research update J Andrews Current neurology and neuroscience reports 9 (1), 59-68, 2009 | 57 | 2009 |
Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development S Paganoni, JD Berry, M Quintana, E Macklin, BR Saville, MA Detry, ... Annals of neurology 91 (2), 165-175, 2022 | 51 | 2022 |
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS JM Shefner, JA Andrews, A Genge, C Jackson, N Lechtzin, TM Miller, ... Amyotrophic lateral sclerosis and frontotemporal degeneration 22 (3-4), 287-299, 2021 | 50 | 2021 |
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis JM Shefner, ME Cudkowicz, O Hardiman, BM Cockroft, JH Lee, FI Malik, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20 (7-8), 584-594, 2019 | 48 | 2019 |
Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study SA Rudnicki, JA Andrews, T Duong, BM Cockroft, FI Malik, L Meng, J Wei, ... Neurotherapeutics 18 (2), 1127-1136, 2021 | 47 | 2021 |
Amyotrophic lateral sclerosis care and research in the United States during the COVID‐19 pandemic: Challenges and opportunities JA Andrews, JD Berry, RH Baloh, N Carberry, ME Cudkowicz, B Dedi, ... Muscle & nerve 62 (2), 182-186, 2020 | 45 | 2020 |
ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics H Mitsumoto, P Factor-Litvak, H Andrews, RR Goetz, L Andrews, ... Amyotrophic lateral sclerosis and frontotemporal degeneration 15 (3-4), 192-203, 2014 | 43 | 2014 |
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis JM Shefner, AA Wolff, L Meng, A Bian, J Lee, D Barragan, JA Andrews, ... Amyotrophic lateral sclerosis and frontotemporal degeneration 17 (5-6), 426-435, 2016 | 41 | 2016 |